SCHEMBL19902529

SCHEMBL19902529

O=C(O)C1CCC(c2n[nH]c(=O)c3ccccc23)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
ATM Q13315 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
POLB P06746 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C1 Q04828 1/20 0.43
PARP1 P09874 3/20 0.42
ROCK2 O75116 4/20 0.41
KDM4E B2RXH2 1/20 0.41
ROCK1 Q13464 4/20 0.41
ALDH1A1 P00352 3/20 0.40
PARP2 Q9UGN5 1/20 0.40
PARP3 Q9Y6F1 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
AR P10275 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789261 0.88 ATM (0.50) LMNANPC1RAB9AATMNPSR1
SCHEMBL19902527 0.87 POLB (0.43) LMNANPC1RAB9AATMNPSR1
SCHEMBL19902538 0.84 SMN1; SMN2 (0.47) NPC1RAB9APOLBPARP1ROCK2
SCHEMBL19902592 0.84 ATM (0.44) LMNANPC1RAB9AATMNPSR1
SCHEMBL19902542 0.82 LMNA (0.49) LMNAATMNPSR1POLBPARP1
SCHEMBL17437872 0.82 ROCK2 (0.53) LMNANPC1RAB9AATMNPSR1
SCHEMBL1786583 0.82 ATM (0.47) LMNANPC1RAB9AATMNPSR1
SCHEMBL1786994 0.82 PRMT5 (0.48) LMNANPC1RAB9AATMNPSR1
SCHEMBL19902312 0.81 PRMT5 (0.45) LMNANPC1RAB9AATMNPSR1
SCHEMBL19902331 0.81 PRMT5 (0.45) LMNANPC1RAB9AATMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 LMNA 1620/4885NPC1 2709/4885RAB9A 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.